| gap-pubmed-20260410- | What determines the differential therapeutic efficacy between DNA-targeted versu | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do some therapeutic approaches show promise in preclinical testing but fail | resolved | 0.78 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What links GenX-induced lipid droplet accumulation to reduced global translation | open | 0.72 | 0.00 | 2026-04-10 | 0 | | neurometabolism |
| gap-pubmed-20260410- | How does predifferentiation GenX exposure establish persistent neurotoxic effect | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodevelopment |
| gap-pubmed-20260410- | What mechanisms explain GenX-induced intracellular C99 accumulation with paradox | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms underlie the hypometabolism in prerolandic regions that produces | open | 0.73 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What is the diagnostic specificity and sensitivity of motor band sign on 18F-FDG | open | 0.87 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does TDP-43 pathology manifest across multiple distinct neurodegenerative di | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the specific molecular mechanisms driving TDP-43 nuclear depletion and | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do 71% of MOGAD patients have undetectable CSF-KFLC despite active demyelina | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What biological mechanisms explain the distinct KFLC-Index patterns across MOGAD | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How do environmental factors modulate the penetrance of genetic risk variants in | open | 0.72 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the mechanisms underlying APOE variant effects on AD risk across differ | resolved | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do rare variants combine with each other and common variants to determine AD | open | 0.78 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does agitation prevalence vary dramatically across different dementia subtyp | open | 0.73 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms cause noradrenergic receptor upregulation in frontal cortex foll | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Do L-carnitine-induced neuronal cells from ADSCs function equivalently to native | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neuroregeneration |
| gap-pubmed-20260410- | How does L-carnitine simultaneously activate both PKA and Wnt/β-catenin pathways | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroregeneration |
| gap-pubmed-20260410- | What determines the selectivity of FcRn blockade for pathogenic versus protectiv | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do engineered FcRn blockers affect neuroinflammation and autoantibody cleara | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does SLC35A2 brain mosaicism in humans compare to complete conditional knock | open | 0.72 | 0.00 | 2026-04-10 | 0 | | translational-neuroscience |
| gap-pubmed-20260410- | Why does oligodendroglial hyperplasia occur in both Emx1 and Olig2 lineage knock | open | 0.76 | 0.00 | 2026-04-10 | 0 | | epilepsy |
| gap-pubmed-20260410- | What molecular mechanisms underlie SLC35A2 deficiency-induced delay in neuronal | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodevelopment |
| gap-pubmed-20260410- | What determines the relative contribution of lipid carrier vs. phytochemical car | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does pH-responsive transition to inverted hexagonal phase enhance therapeuti | open | 0.80 | 0.00 | 2026-04-10 | 0 | | nanomedicine |
| gap-pubmed-20260410- | Why does microglial BTK activation lead to impaired phagocytosis rather than enh | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does BTK integrate DNA-sensing and TLR signals to specifically activate the | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What mechanisms explain BTK's differential effects on PI3K-AKT-mTOR signaling ve | resolved | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does the D395A mutation's location/properties relate to the selective neurod | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms determine why VCP mutations cause isolated FTD versus | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does DHE-mediated TREM2 activation restore mitochondrial function in microgl | open | 0.74 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What is the therapeutic window and dose-response relationship for DHE in chronic | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does DHE binding to TREM2 structurally activate the receptor and initiate do | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How do regional differences in circadian transcription vulnerability relate to A | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms cause region-specific circadian disruption before amyloid plaque | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do thyromimetics simultaneously prevent axonal degeneration while promoting | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the molecular mechanisms by which thyromimetics prevent oligodendrocyte | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What signaling pathways link neuroinflammatory stimuli to enhanced PINK1/HK2-dep | resolved | 0.81 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does glucose availability regulate the PINK1/HK2 complex formation and mitop | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms enable PINK1-dependent mitophagy to occur more rapidly | resolved | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms allow ocrelizumab-treated patients to maintain normal T-cell res | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Why do immune responses fail to correlate with COVID-19 severity in MS patients | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Does ANXA1-mediated autophagy enhancement translate to neuroprotection in actual | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does ANXA1 mechanistically regulate CAMK2 phosphorylation in oxidative stres | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do CRISPRa-identified reprogramming factors compare to traditional overexpre | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms determine which neuronal subtypes astrocytes reprogram | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Will evolving SARS-CoV-2 variants with reduced severity maintain neurotropic pot | open | 0.78 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines whether SARS-CoV-2 nucleocapsid protein forms pathological vs. f | resolved | 0.86 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do SARS-CoV-2 proteins mechanistically accelerate pathological fibril format | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does tumor resection incompletely reverse gut barrier dysfunction and bacter | open | 0.74 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |